For research use only. Not for therapeutic Use.
SPR719（Cat No.:I018007）is an investigational antibiotic with promising activity against various bacterial infections, particularly those caused by Gram-positive pathogens. As a novel molecule, it operates through a unique mechanism that targets bacterial cell wall synthesis, enhancing its efficacy against resistant strains. SPR719 is currently being studied for its potential to treat serious infections, including those associated with antibiotic resistance. Preclinical studies suggest it may offer a new therapeutic option in the fight against multidrug-resistant bacteria. Ongoing research aims to further evaluate its safety and effectiveness in clinical settings.
| Catalog Number | I018007 |
| CAS Number | 1384984-18-2 |
| Molecular Formula | C₂₁H₂₅FN₆O₃ |
| Purity | ≥95% |
| IUPAC Name | 1-ethyl-3-[5-fluoro-6-[2-(2-hydroxypropan-2-yl)pyrimidin-5-yl]-4-[(2R)-oxolan-2-yl]-1H-benzimidazol-2-yl]urea |
| InChI | InChI=1S/C21H25FN6O3/c1-4-23-20(29)28-19-26-13-8-12(11-9-24-18(25-10-11)21(2,3)30)16(22)15(17(13)27-19)14-6-5-7-31-14/h8-10,14,30H,4-7H2,1-3H3,(H3,23,26,27,28,29)/t14-/m1/s1 |
| InChIKey | BKUISYCLLXCBJV-CQSZACIVSA-N |
| SMILES | CCNC(=O)NC1=NC2=C(N1)C=C(C(=C2[C@H]3CCCO3)F)C4=CN=C(N=C4)C(C)(C)O |
| Reference | [1]. Locher CP, et al. A novel inhibitor of gyrase B is a potent drug candidate for treatment of tuberculosis and nontuberculosis mycobacterial infections. Antimicrob Agents Chemother. 2015 Mar;59(3):1455-65. |
